University of Sussex
Browse

File(s) not publicly available

Bendamustine as a model for the activity of alkylating agents

journal contribution
posted on 2023-06-08, 21:27 authored by Christos Apostolopoulos, Leandro CastellanoLeandro Castellano, Justin Stebbing, Georgios GiamasGeorgios Giamas
Attempts to administer personalized standard cytotoxic chemotherapy based on individual patient characteristics have been disappointing. Alkylating agents are one of the oldest classes of anticancer medicine with a wide variety of molecular actions and thus the potential for broad utility. Bendamustine hydrochloride, a new addition to this class, was previously developed in the 1960s and has now been trialled in hematological malignancies and many solid tumor types as monotherapy or in combination with the known standard of care. It appears to occupy a particular role in resistant or refractory hematological disease and it was approved by the US FDA for the treatment of chronic lymphocytic leukemia in March 2008. Further trials will reveal whether it is likely to become incorporated into front-line regimens in non-Hodgkin's lymphoma and other malignancies.

History

Publication status

  • Published

Journal

Future Oncology

ISSN

1479-6694

Publisher

Future Medicine

Issue

3

Volume

4

Page range

323-332

Department affiliated with

  • Biochemistry Publications

Full text available

  • No

Peer reviewed?

  • Yes

Legacy Posted Date

2015-07-07

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC